Affordable Access

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers.

Authors
  • Mathieu, Morgan G
  • Linley, Adam J
  • Reeder, Stephen P
  • Badoual, Cécile
  • Tartour, Eric
  • Rees, Robert C
  • McArdle, Stéphanie E B
Type
Published Article
Journal
Cancer immunity
Publication Date
Jan 01, 2010
Volume
10
Pages
2–2
Identifiers
PMID: 20058853
Source
Medline
License
Unknown

Abstract

The search for novel tumour antigens that are either uniquely expressed or over-expressed in a wide variety of tumours is still ongoing. Because of their expression in a broad spectrum of cancers and limited expression in normal tissues, cancer/testis antigens are considered to be potentially reliable targets for immunotherapy of cancer in general. The helicase antigen HAGE has been identified as a cancer/testis antigen. However, little is known about its expression in normal and cancer tissues. Using a newly developed antibody against HAGE, specific staining of its expression by immunohistochemistry was validated and optimised on murine tumours transfected to express the HAGE protein. The antibody was subsequently used to determine HAGE expression in normal human and cancer tissue microarrays. HAGE protein expression was confirmed in 75% (12/16) of carcinomas as compared to normal tissues, which either did not express HAGE at all or expressed HAGE at very low levels with the exception of testis. Interestingly, discrepancies were also found between mRNA analysis by real time quantitative PCR (RT-qPCR) and protein analysis by immunohistochemistry, emphasising the need to validate the expression of cancer/testis antigens at the protein level prior to the development of new vaccine strategies. HAGE is therefore proposed to be a valid candidate for designing a broad spectrum vaccine against cancer.

Report this publication

Statistics

Seen <100 times